Stonebridge Capital Advisors LLC raised its position in shares of Gilead Sciences (NASDAQ:GILD) by 1.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 76,288 shares of the biopharmaceutical company’s stock after purchasing an additional 1,010 shares during the quarter. Gilead Sciences accounts for 1.3% of Stonebridge Capital Advisors LLC’s investment portfolio, making the stock its 24th biggest holding. Stonebridge Capital Advisors LLC’s holdings in Gilead Sciences were worth $5,465,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in GILD. Welch Investments LLC acquired a new position in shares of Gilead Sciences in the third quarter worth $108,000. Wealthcare Advisory Partners LLC acquired a new position in shares of Gilead Sciences in the third quarter worth $133,000. Horan Capital Advisors LLC. acquired a new position in shares of Gilead Sciences in the third quarter worth $144,000. Hanson & Doremus Investment Management increased its stake in shares of Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the last quarter. Finally, Rowland & Co. Investment Counsel ADV acquired a new position in shares of Gilead Sciences in the second quarter worth $153,000. 78.40% of the stock is currently owned by institutional investors.
GILD stock opened at $74.01 on Tuesday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $89.54. The stock has a market cap of $96,093.74, a price-to-earnings ratio of 8.65, a PEG ratio of -1.67 and a beta of 1.18.
The company also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.08%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend was Thursday, March 15th. Gilead Sciences’s dividend payout ratio is 26.64%.
In other Gilead Sciences news, Director John Francis Cogan sold 5,833 shares of the company’s stock in a transaction dated Friday, April 20th. The shares were sold at an average price of $73.74, for a total transaction of $430,125.42. Following the completion of the sale, the director now directly owns 58,452 shares in the company, valued at $4,310,250.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robin L. Washington sold 5,000 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the sale, the chief financial officer now owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The disclosure for this sale can be found here. Insiders have sold 314,433 shares of company stock valued at $24,758,352 over the last 90 days. Corporate insiders own 1.16% of the company’s stock.
GILD has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. BMO Capital Markets reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, January 3rd. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, Wells Fargo raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $79.02 to $96.00 in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $88.65.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences (GILD) Holdings Increased by Stonebridge Capital Advisors LLC” was posted by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://weekherald.com/2018/04/24/gilead-sciences-gild-holdings-increased-by-stonebridge-capital-advisors-llc.html.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.